622 related articles for article (PubMed ID: 17709460)
21. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
[TBL] [Abstract][Full Text] [Related]
22. Antibiotic treatment outcomes in community-acquired pneumonia.
Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
[TBL] [Abstract][Full Text] [Related]
23. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia.
Teh B; Grayson ML; Johnson PD; Charles PG
Clin Microbiol Infect; 2012 Apr; 18(4):E71-3. PubMed ID: 22284533
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and management of community-acquired pneumonia in adults.
Watkins RR; Lemonovich TL
Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
[TBL] [Abstract][Full Text] [Related]
25. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
Weiss K; Tillotson GS
Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
[TBL] [Abstract][Full Text] [Related]
26. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia.
Wilson BZ; Anzueto A; Restrepo MI; Pugh MJ; Mortensen EM
Crit Care Med; 2012 Aug; 40(8):2310-4. PubMed ID: 22622401
[TBL] [Abstract][Full Text] [Related]
27. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
[TBL] [Abstract][Full Text] [Related]
28. Severe community-acquired pneumonia treated with β-lactam-respiratory quinolone vs. β-lactam-macrolide combination.
Karhu J; Ala-Kokko TI; Ohtonen P; Syrjälä H
Acta Anaesthesiol Scand; 2013 May; 57(5):587-93. PubMed ID: 23379766
[TBL] [Abstract][Full Text] [Related]
29. Antibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicentre cluster-randomised cross-over trial.
van Werkhoven CH; Postma DF; Oosterheert JJ; Bonten MJ
Neth J Med; 2014 Apr; 72(3):170-8. PubMed ID: 24846935
[TBL] [Abstract][Full Text] [Related]
30. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
Mortensen EM; Restrepo MI; Anzueto A; Pugh J
Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
[TBL] [Abstract][Full Text] [Related]
31. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
32. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis.
Vardakas KZ; Trigkidis KK; Falagas ME
Clin Microbiol Infect; 2017 Apr; 23(4):234-241. PubMed ID: 27965070
[TBL] [Abstract][Full Text] [Related]
33. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Martinez FJ
Clin Infect Dis; 2004 May; 38 Suppl 4():S328-40. PubMed ID: 15127366
[TBL] [Abstract][Full Text] [Related]
34. Narrow-spectrum ß-lactam monotherapy in hospital treatment of community-acquired pneumonia: a register-based cohort study.
Rhedin S; Galanis I; Granath F; Ternhag A; Hedlund J; Spindler C; Naucler P
Clin Microbiol Infect; 2017 Apr; 23(4):247-252. PubMed ID: 28017793
[TBL] [Abstract][Full Text] [Related]
35. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis.
Ott SR; Hauptmeier BM; Ernen C; Lepper PM; Nüesch E; Pletz MW; Hecht J; Welte T; Bauer TT
Eur Respir J; 2012 Mar; 39(3):611-8. PubMed ID: 21965229
[TBL] [Abstract][Full Text] [Related]
36. Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.
Ambroggio L; Test M; Metlay JP; Graf TR; Blosky MA; Macaluso M; Shah SS
Pediatr Pulmonol; 2016 May; 51(5):541-8. PubMed ID: 26367389
[TBL] [Abstract][Full Text] [Related]
37. Prescription of antibiotics for adults hospitalized with community-acquired pneumonia in Korea in 2004: a population-based descriptive study.
Yoon YK; Kim EJ; Chun BC; Eom JS; Park DW; Sohn JW; Kim MJ
Respirology; 2012 Jan; 17(1):172-9. PubMed ID: 21995414
[TBL] [Abstract][Full Text] [Related]
38. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
An MM; Zou Z; Shen H; Gao PH; Cao YB; Jiang YY
Int J Antimicrob Agents; 2010 Jul; 36(1):58-65. PubMed ID: 20400271
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home.
Chen JI; Slater LN; Kurdgelashvili G; Husain KO; Gentry CA
Ann Pharmacother; 2013 Jan; 47(1):9-19. PubMed ID: 23324506
[TBL] [Abstract][Full Text] [Related]
40. Addition of macrolide in treating adult hospitalized community-acquired pneumonia.
Loh LC; Quah SY; Khoo SK; Vijayasingham P; Thayaparan T
Respirology; 2005 Jun; 10(3):371-7. PubMed ID: 15955152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
